CHICAGO, IL - Long Grove Pharmaceuticals, LLC, a manufacturer of differentiated pharmaceuticals, is filling a critical supply shortage of Fluorescein Injection, USP. In June 2023, Long Grove Pharmaceuticals acquired the New Drug Application (NDA) for AK-FLUOR. The company has reached a distribution agreement with the Food and Drug Administration (FDA) Office of Drug Shortages to make available existing inventory of AK-FLUOR, Fluorescein Injection, USP manufactured by Akorn Pharmaceuticals.
AK-FLUOR is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. It is currently available in the following presentations:
- 10% (100mg/mL 5mL vials) 12 pack
- 25% (250mg/mL 2mL vials) 12 pack
Fluorescein Injection, USP is currently impacted by a supply shortage resulting from Akorn Pharmaceuticals’ exit from the U.S. market. To ensure the consistent availability of Fluorescein Injection, USP prior to its relaunch as a Long Grove Pharmaceuticals product, Long Grove Pharmaceuticals will make available the existing AK-FLUOR inventory manufactured by Akorn Pharmaceuticals in both 10% and 25% solutions.
“Our goal is to provide the market a consistent supply of this essential medication now and after its relaunch as a Long Grove-labeled product,” said Peter Karas, Chief Commercial Officer at Long Grove Pharmaceuticals. “Until we can fill the gap in supply through our own manufacturing, the existing Akorn-manufactured product will assist in easing procurement burdens for ophthalmic providers and health systems.”
For more information about Long Grove Pharmaceuticals and AK-FLUOR, visit www.longgrovepharma.com.
